PUBLICATIONS

Explore our posters and presentations.

We are passionate about our mission to curve HBV and coronaviruses, as well as our voice in the scientific community. That’s why we regularly publish meaningful content on our dynamic pipeline of therapeutics. Explore our scientific publications by format or asset.

Arbutus Publications
Poster | June 25, 2022

Continued suppression of viral markers observed following discontinuation of nucleos(t)ide analogue therapy in chronic hepatitis B subjects with low hepatitis B surface antigen levels after 48 weeks of treatment with AB-729

Continued suppression of viral markers observed following discontinuation of nucleos(t)ide analogue therapy in chronic hepatitis B subjects with low hepatitis B surface antigen levels after 48 weeks of treatment with AB-729
Poster | June 25, 2022

Safety, tolerability, pharmacokinetics (PK), and antiviral activity of the 3rd generation capsid inhibitor AB-836 in healthy subjects (HS) and subjects with chronic hepatitis B (CHB)

Safety, tolerability, pharmacokinetics (PK), and antiviral activity of the 3rd generation capsid inhibitor AB-836 in healthy subjects (HS) and subjects with chronic hepatitis B (CHB)
Poster | June 25, 2022

Long-term HBsAg suppression maintained after cessation of AB-729 treatment and comparable on-treatment response observed in HBeAg+ subjects

Long-term HBsAg suppression maintained after cessation of AB-729 treatment and comparable on-treatment response observed in HBeAg+ subjects
Poster | June 25, 2022

Pharmacodynamics of durable HBsAg suppression by AB-729 short interfering RNA correlates with pharmacokinetics of RNA-induced silencing complex (RISC) loading within liver

Pharmacodynamics of durable HBsAg suppression by AB-729 short interfering RNA correlates with pharmacokinetics of RNA-induced silencing complex (RISC) loading within liver
Poster | June 25, 2022

Inhibition of hepatitis B surface antigen by RNA interference therapeutic AB-729 is associated with increased cytokine signatures in HBV DNA+ chronic hepatitis B subjects

Inhibition of hepatitis B surface antigen by RNA interference therapeutic AB-729 is associated with increased cytokine signatures in HBV DNA+ chronic hepatitis B subjects
Poster | June 25, 2022

Reduction of hepatitis B surface antigen mediated by RNA interference therapeutic AB-729 in chronic hepatitis B patients is associated with T cell activation and a decline in exhausted CD8 T cells

Reduction of hepatitis B surface antigen mediated by RNA interference therapeutic AB-729 in chronic hepatitis B patients is associated with T cell activation and a decline in exhausted CD8 T cells
Poster | June 25, 2022

Preclinical activity of small-molecule oral PD-L1 checkpoint inhibitors capable of reinvigorating T cell responses from chronic hepatitis B patients

Preclinical activity of small-molecule oral PD-L1 checkpoint inhibitors capable of reinvigorating T cell responses from chronic hepatitis B patients
Poster | March 11, 2022

Inhibition of PAPD5 and PAPD7 by Small-Molecule HBV RNA Destabilizers from DHQ and THP Chemical Series

International Conference on Antiviral Research (ICAR)

Inhibition of PAPD5 and PAPD7 by Small-Molecule HBV RNA Destabilizers from DHQ and THP Chemical Series
Presentation | December 7, 2021

Progress Toward an HBV Cure Combination Therapy

Hep DART 2021

Progress Toward an HBV Cure Combination Therapy
Poster | November 12, 2021

Low HBsAg levels maintained following cessation of the GalNAc-siRNA, AB-729, in chronic hepatitis B subjects on nucleos(t)ide analogue therapy 

Low HBsAg levels maintained following cessation of the GalNAc-siRNA, AB-729, in chronic hepatitis B subjects on nucleos(t)ide analogue therapy 
Presentation | October 11, 2021

Clinical Overview of AB-729, a potent siRNA in development for the treatment of chronic hepatitis B infection

The Science of HBV Cure Meeting 2021 (Virtual)

Clinical Overview of AB-729, a potent siRNA in development for the treatment of chronic hepatitis B infection
Poster | September 26, 2021

Kinetics of HBV DNA replication, cccDNA formation and HBsAg production in a “pgRNA launch” HBV replication system and its susceptibility to antiviral agents

2021 International HBV Meeting

Kinetics of HBV DNA replication, cccDNA formation and HBsAg production in a “pgRNA launch” HBV replication system and its susceptibility to antiviral agents
Presentation | June 28, 2021

Clinical Update Based on Data Presented at the EASL International Liver Congress™ 2021

EASL International Liver Congress™ 2021

Clinical Update Based on Data Presented at the EASL International Liver Congress™ 2021
Presentation | June 23, 2021

Preclinical antiviral profile of AB-836, a potent, highly selective hepatitis B virus capsid inhibitor

EASL International Liver Congress™ 2021

Preclinical antiviral profile of AB-836, a potent, highly selective hepatitis B virus capsid inhibitor
Poster | June 23, 2021

Inhibition of hepatitis B surface antigen in chronic hepatitis B subjects by RNA interference therapeutic AB-729 is accompanied by upregulation of HBV-specific T-cell activation markers

EASL International Liver Congress™ 2021

Inhibition of hepatitis B surface antigen in chronic hepatitis B subjects by RNA interference therapeutic AB-729 is accompanied by upregulation of HBV-specific T-cell activation markers
Poster | June 23, 2021

Inhibition of hepatitis B surface antigen by RNA interference therapeutic AB-729 in chronic hepatitis B patients correlates with suppression of all HBsAg isoforms and HBV RNA

EASL International Liver Congress™ 2021

Inhibition of hepatitis B surface antigen by RNA interference therapeutic AB-729 in chronic hepatitis B patients correlates with suppression of all HBsAg isoforms and HBV RNA
Poster | June 23, 2021

A single dose of the GalNAc-siRNA AB-729 results in prolonged reductions in HBsAg, HBcrAg, HBV DNA and HBV RNA in the absence of nucleos(t)ide analogue therapy in HBeAg- subjects with chronic hepatitis B infection

EASL International Liver Congress™ 2021

A single dose of the GalNAc-siRNA AB-729 results in prolonged reductions in HBsAg, HBcrAg, HBV DNA and HBV RNA in the absence of nucleos(t)ide analogue therapy in HBeAg- subjects with chronic hepatitis B infection
Presentation | June 23, 2021

Repeat dosing of the GalNAc-siRNA AB-729 in subjects with chronic hepatitis B results in robust and sustained HBsAg suppression

EASL International Liver Congress™ 2021

Repeat dosing of the GalNAc-siRNA AB-729 in subjects with chronic hepatitis B results in robust and sustained HBsAg suppression
Presentation | May 5, 2021

An RNAi for the Treatment of Chronic Hepatitis B Infection: Clinical Update

Chronic Hepatitis B Drug Development Summit

An RNAi for the Treatment of Chronic Hepatitis B Infection: Clinical Update
Presentation | February 4, 2021

AB‐729, a GalNAc‐siRNA, results in robust reductions of HBV DNA and HBsAg in subjects with chronic hepatitis B infection APASL 2021

AB‐729, a GalNAc‐siRNA, results in robust reductions of HBV DNA and HBsAg in subjects with chronic hepatitis B infection APASL 2021
Presentation | November 16, 2020

AB-729 Clinical Update 

AB-729 Clinical Update 
Presentation | November 15, 2020

Safety and pharmacodynamics of the GalNAc-siRNA AB-729 in subjects with chronic hepatitis B infection

The Liver Meeting Digital Experience™ | AASLD

Safety and pharmacodynamics of the GalNAc-siRNA AB-729 in subjects with chronic hepatitis B infection
Presentation | May 18, 2020

AB-729 Clinical Update

AB-729 Clinical Update
Presentation | March 26, 2020

AB-729 Clinical Update

AB-729 Clinical Update
Suppress Reduce Boost

HBV

Learn about our three-pronged Suppress, Reduce, Boost approach to HBV.

Discover Our HBV Assets

Pan Coronavirus Treatment

Coronavirus

Learn more about how we are innovating in pan-coronavirus treatment.

Discover Our Coronavirus Assets